Influence of human papillomavirus and p16INK4a on treatment outcome of patients with anal cancer

Koerber, Stefan A.; Schoneweg, Clara; Slynko, Alla; Krug, David; Haefner, Matthias F.; Herfarth, Klaus; Debus, J.; Sterzing, Florian; Doeberitz, Magnus von Knebel; Prigge, Elena-Sophie; Reuschenbach, Miriam

doi:10.1016/j.radonc.2014.11.013

Cited by 54 publications

(51 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, HPV16 and/ or p16 positive tumors have shown higher sensitivity to CMT, and this biological characteristic should thus be added to the prognostic armamentarium [28,29].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of a 36 Gy elective node irradiation dose in anal cancer

Lepinoy

Lescut

Puyraveau

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…Recently, HPV16 and/ or p16 positive tumors have shown higher sensitivity to CMT, and this biological characteristic should thus be added to the prognostic armamentarium [28,29].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of a 36 Gy elective node irradiation dose in anal cancer

Lepinoy

Lescut

Puyraveau

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…Mai et al additionally report an independent association between combined HPV/p16 status and PFS (Mai et al , 2015). In contrast, Koerber and Meulendijks identified no independent associations for HPV or p16 alone, but reported combined HPV and p16 to be predictive of both PFS and OS (Koerber et al , 2014; Meulendijks et al , 2015). …”

Section: Current Biomarkers Of Response To Chemoradiotherapymentioning

confidence: 92%

Biomarkers in anal cancer: from biological understanding to stratified treatment

et al. 2016

View full text Add to dashboard Cite

Squamous cell carcinomas of the anus and anal canal represent a model of a cancer and perhaps the first where level 1 evidence supported primary chemoradiotherapy (CRT) in treating locoregional disease with curative intent. The majority of tumours are associated with infection with oncogenic subtypes of human papilloma virus and this plays a significant role in their sensitivity to treatment. However, not all tumours are cured with CRT and there remain opportunities to improve outcomes in terms of oncological control and also reducing late toxicities. Understanding the biology of ASCC promises to allow a more personalised approach to treatment, with the development and validation of a range of biomarkers and associated techniques that are the focus of this review.

show abstract

“…HPV is a DNA virus that is implicated in the carcinogenesis of neoplasms in the cervix, oropharynx, and anus [7,8]. HPV DNA integrates with the host DNA, allowing for the production of viral proteins E6 and E7.…”

Section: Introductionmentioning

confidence: 99%

Treatment de-intensification strategies for head and neck cancer

Kelly

Husain

Burtness

2016

European Journal of Cancer

101

View full text Add to dashboard Cite

Increasingly, squamous cell carcinoma of the oropharynx (OPSCC) is attributable to transformation resulting from high-risk human papillomavirus (HPV) infection. Such cancers are significantly more responsive to treatment than traditional tobacco- and alcohol-associated squamous cell cancers of the head and neck. Conventional management with definitive chemoradiation, surgery and adjuvant radiation, or radiation given with altered fractionation schemes, while effective, incurs long-term morbidity that escalates with treatment intensity and significantly impairs quality of life. Recent trials have suggested that less intensive treatment regimens may achieve similar efficacy with decreased toxicity. In this article, we review the primary strategies used for de-escalation of treatment, which include the reduction of radiation dose, substitution and/or elimination of concurrent radiosensitising chemotherapy, and the use of minimally invasive surgery. We discuss the rationale behind these approaches and the preliminary data demonstrating the success of de-escalation, as well as potential considerations raised by treatment de-intensification in HPV-associated OPSCC.

show abstract

Influence of human papillomavirus and p16INK4a on treatment outcome of patients with anal cancer

Abstract: The combination of HPV-DNA and p16 can be used as an independent prognostic parameter in anal cancer patients.

Cited by 54 publications

References 37 publications

Evaluation of a 36 Gy elective node irradiation dose in anal cancer

Evaluation of a 36 Gy elective node irradiation dose in anal cancer

Biomarkers in anal cancer: from biological understanding to stratified treatment

Treatment de-intensification strategies for head and neck cancer

Contact Info

Product

Resources

About